On October 27, Professor Pan Wenzhi from Zhongshan Hospital, representing the teams of Academician Ge Junbo and Professor Zhou Daxin, presented the two-year follow-up data from the NXT-DURA trial of the transfemoral TaurusNXT TAVR system at TCT’s valve innovation session. This marked the first presentation of a China-developed dry-tissue TAVR system at TCT in the United States.

Safety endpoints showed no coronary obstruction, accessrelated vascular complications, or valve embolization events, with a one-year cardiovascular mortal ity rate of 0.7%. The patient demonstrated favourable outcomes following implantation of the TaurusNXT system, with echocardiographic follow-up results at one year and partial two-year follow-up showing: 

• moderate or higher paravalvular leak remained below 2% 

• mean LVEF stabilized above 63% 

• EOA reached 1.8 cm² at one year and 2.1 cm² at two years